---
title: The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms
nct_id: NCT02495311
overall_status: UNKNOWN
sponsor: Far Eastern Memorial Hospital
study_type: OBSERVATIONAL
primary_condition: Adenomyosis
countries: Taiwan
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02495311.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02495311"
ct_last_update_post_date: 2023-09-15
last_seen_at: "2026-05-12T07:21:27.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms

**Official Title:** The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms and Gastrointestinal Symptoms

**NCT ID:** [NCT02495311](https://clinicaltrials.gov/study/NCT02495311)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 150
- **Lead Sponsor:** Far Eastern Memorial Hospital
- **Conditions:** Adenomyosis, Uterine Leiomyoma
- **Start Date:** 2014-11-15
- **Completion Date:** 2024-12-31
- **CT.gov Last Update:** 2023-09-15

## Brief Summary

The aim of this study is to assess the relationship between adenomyosis/myoma and lower urinary tract symptoms, sexual function and gastrointestinal symptoms.

## Detailed Description

All outpatient patients were found to have \>3 cm uterine myoma or adenomyosis were invited to participate in this study. The size and location of uterine myoma or adenomyosis and the uterus should be assessed by ultrasonography. Besides, all enrolled female patients will be asked to complete overactive bladder symptom score, female bladder function (UDI-6 \& IIQ-7), female sexual function index, and bowel incontinence assessment questionnaires. In addition, patients who underwent surgeries for myoma or adenomyosis will be requested to complete the above questionnaires at 3 months after surgery. Women with intact uterus should be assessed again by ultrasonography. At least 30 women with age and body mass index matched and without uterine myoma or adenomyosis will be invited to participate in this study as the control group.

## Eligibility

- **Minimum age:** 20 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** Yes

```
\<Women with myoma or adenomyosis\>

Inclusion Criteria:

1. \>20 years old.
2. Myoma: women with \>3 cm uterine myoma
3. Adenomyosis: women with uterus having several dark area (lacunar areas) in one uterine wall or thickening uterine wall

\<The control group\>

Inclusion criteria:

1. \>20 years old.
2. Women without myoma or adenomyosis

\<Both groups\>

Exclusion Criteria:

1. The patient has a lower urinary tract infection or acute intestinal inflammation.
2. Previous surgery for the bladder or urethra.
3. History of urinary tract stones or tumors.
```

## Arms

- **Women with uterine myoma** — Women with uterine myoma
- **Women with adenomyosis** — Women with adenomyosis
- **Women without uterine myoma or adenomyosis** — Control group

## Interventions

- **myomectomy or adenomyomectomy** (PROCEDURE)

## Primary Outcomes

- **The corrleation coefficient between the size of myoma and Overactive Bladder Symptoms Scores** _(time frame: 12 weeks)_ — The Spearman's correlation between the size of uterine myoma and the score of Overactive Bladder Symptoms Scores

## Secondary Outcomes

- **The corrleation coefficient between the size of myoma and the presence of constipation/diarrhea** _(time frame: 12 weeks)_
- **Comparison of Overactive Bladder Symptoms Scores between the adenomyosis group and the control group** _(time frame: 12 weeks)_
- **Comparisons of the constipation/diarrhea rates between the adenomyosis group and the control group** _(time frame: 12 weeks)_

## Locations (1)

- Far-Eastern Memorial Hospital, Banqiao District, New Taipei, Taiwan — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.far-eastern memorial hospital|banqiao district|new taipei|taiwan` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02495311.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02495311*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*